Therefore, angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may mitigate and reduce the risk of ACS and MI through the upregulation of cardioprotective ACE2 with the regulation of the balance of Ang II/Ang‐17 axis, which prevents inflammation and thrombosis.123. Here, ACE2 is linked to myocardial infarction.